Regeneron Pharmaceuticals (REGN) EPS: History & Chart

Regeneron Pharmaceuticals, Inc.(REGN)

Biotechnology · Tarrytown, NY

$810.31+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Tarrytown, NY

15,410 employees

www.regeneron.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Leonard S. Schleifer

View full financials

REGN Earnings Per Share (EPS) Metrics

EARNINGS PER SHARE (EPS)

40.43

EARNINGS PER SHARE (EPS) AVG TTM

41.98

EARNINGS PER SHARE (EPS) AVG 3Y

40.38

EARNINGS PER SHARE (EPS) AVG 5Y

45.10

EARNINGS PER SHARE (EPS) AVG 10Y

30.66

EARNINGS PER SHARE (EPS) AVG 15Y

21.82

EARNINGS PER SHARE (EPS) AVG 20Y

16.29

CURRENT VS TTM AVG

-3.70%

CURRENT VS 3Y AVG

+0.12%

CURRENT VS 5Y AVG

-10.35%

CURRENT VS 10Y AVG

+31.87%

CURRENT VS 15Y AVG

+85.33%

CURRENT VS 20Y AVG

+148.20%

NAME	MARKET CAP	EARNINGS PER SHARE (EPS)	TTM	3Y	5Y
Regeneron Pharmaceuticals, Inc. (REGN)	$83.48B	40.43	41.98	40.38	45.10
HCA Healthcare, Inc. (HCA)vs ›	$87.04B	29.87	25.45	22.39	20.36
Elevance Health Inc. (ELV)vs ›	$87.17B	22.50	25.49	25.23	24.07
Cigna Corporation (CI)vs ›	$72.89B	24.16	17.27	18.45	18.81
GSK plc (GSK)vs ›	$97.25B	3.16	2.69	4.37	4.18
Boston Scientific Corporation (BSX)vs ›	$66.86B	2.46	1.61	1.19	0.89
Sanofi (SNY)vs ›	$103.62B	0.56	3.01	2.95	3.44
Cencora, Inc. (COR)vs ›	$63.17B	13.46	7.81	8.10	3.88
McKesson Corporation (MCK)vs ›	$104.10B	37.37	32.20	28.04	15.41
Stryker Corporation (SYK)vs ›	$105.97B	9.65	8.18	7.73	6.75

NAME

MARKET CAP

EARNINGS PER SHARE (EPS)

TTM

Regeneron Pharmaceuticals, Inc. (REGN)

$83.48B

40.43

41.98

40.38

45.10

HCA Healthcare, Inc. (HCA)vs ›

$87.04B

29.87

25.45

22.39

20.36

Elevance Health Inc. (ELV)vs ›

$87.17B

22.50

25.49

25.23

24.07

Cigna Corporation (CI)vs ›

$72.89B

24.16

17.27

18.45

18.81

GSK plc (GSK)vs ›

$97.25B

3.16

2.69

4.37

4.18

Boston Scientific Corporation (BSX)vs ›

$66.86B

2.46

1.61

1.19

0.89

Sanofi (SNY)vs ›

$103.62B

0.56

3.01

2.95

3.44

Cencora, Inc. (COR)vs ›

$63.17B

13.46

7.81

8.10

3.88

McKesson Corporation (MCK)vs ›

$104.10B

37.37

32.20

28.04

15.41

Stryker Corporation (SYK)vs ›

$105.97B

9.65

8.18

7.73

6.75

Earnings Per Share (EPS) FAQ

What is the earnings per share (EPS) for Regeneron Pharmaceuticals, Inc. (REGN)?

The earnings per share (EPS) for REGN stock is 40.43.

Is Regeneron Pharmaceuticals, Inc.'s earnings per share (EPS) high or low?

The earnings per share (EPS) of 40.43 is 10% below its 5-year average of 45.10, near the low end of its 5-year range (32.65–76.40).

What is the TTM average earnings per share (EPS) for Regeneron Pharmaceuticals, Inc. (REGN)?

The TTM average earnings per share (EPS) for REGN stock is 41.98.

What is the 3Y average earnings per share (EPS) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 3Y average earnings per share (EPS) for REGN stock is 40.38.

What is the 5Y average earnings per share (EPS) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 5Y average earnings per share (EPS) for REGN stock is 45.10.

What is the 10Y average earnings per share (EPS) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 10Y average earnings per share (EPS) for REGN stock is 30.66.

What is the 15Y average earnings per share (EPS) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 15Y average earnings per share (EPS) for REGN stock is 21.82.

What is the 20Y average earnings per share (EPS) for Regeneron Pharmaceuticals, Inc. (REGN)?

The 20Y average earnings per share (EPS) for REGN stock is 16.29.

DATE	EARNINGS PER SHARE (EPS)
2025-12-31	43.07
2024-12-31	40.90
2023-12-31	37.05
2022-12-31	40.51
2021-12-31	76.40
2020-12-31	32.65
2019-12-31	19.38
2018-12-31	21.29
2017-12-31	11.27
2016-12-31	8.55
2015-12-31	6.17
2014-12-31	3.36
2013-12-31	4.23
2012-12-31	7.92
2011-12-31	-2.45
2010-12-31	-1.26
2009-12-31	-0.85
2008-12-31	-1.05
2007-12-31	-1.59
2006-12-31	-1.77
2005-12-31	-1.71
2004-12-31	0.75
2003-12-31	-2.13
2002-12-31	-2.83
2001-12-31	-1.81
2000-12-31	-0.66
1999-12-31	-0.74
1998-12-31	-0.28
1997-12-31	-0.40
1996-12-31	-1.32

DATE

EARNINGS PER SHARE (EPS)

2025-12-31

43.07

2024-12-31

40.90

2023-12-31

37.05

2022-12-31

40.51

2021-12-31

76.40

2020-12-31

32.65

2019-12-31

19.38

2018-12-31

21.29

2017-12-31

11.27

2016-12-31

8.55

2015-12-31

6.17

2014-12-31

3.36

2013-12-31

4.23

2012-12-31

7.92

2011-12-31

-2.45

2010-12-31

-1.26

2009-12-31

-0.85

2008-12-31

-1.05

2007-12-31

-1.59

2006-12-31

-1.77

2005-12-31

-1.71

2004-12-31

0.75

2003-12-31

-2.13

2002-12-31

-2.83

2001-12-31

-1.81

2000-12-31

-0.66

1999-12-31

-0.74

1998-12-31

-0.28

1997-12-31

-0.40

1996-12-31

-1.32

Earnings Per Share (EPS): 40.43

REGN Earnings Per Share (EPS)

REGN Quarterly EPS Growth (YoY)

REGN P/E Ratio

REGN P/E Ratio Chart

REGN Average Earnings Per Share (EPS) Chart

REGN Current vs Average Earnings Per Share (EPS) Chart

REGN Earnings Per Share (EPS) Metrics

REGN Competitors' Earnings Per Share (EPS)

EPS Comparison

Earnings Per Share (EPS) Formula & Definition

Earnings Per Share (EPS) FAQ

REGN Earnings Per Share (EPS) History

Related Metrics

REGN PEG Ratio

REGN PEG Ratio Chart